Home › Companies › QTTB

Q32 Bio

QTTB Lead: Phase 2

Dermatology Protein

Most recent annual filing: 2026-03-10

Pipeline (2 active programs)

bempikibart

ADX-914

Protein Target: IL-7Rα, IL-7, TSLP

Alopecia Areata Phase 2 subcutaneous

ADX-096

Protein Target: C3d

Undisclosed indication Preclinical

Technology platforms

Tissue-Targeted Complement Inhibitor Platform

Proprietary platform designed to inhibit complement activation in tissue while minimizing systemic complement blockade. Generates tissue-targeted inhibitors of complement activation. Focus areas include ophthalmologic indications and a broad range of autoimmune and inflammatory diseases driven by complement dysregulation. Assets include ADX-096 and other early-stage C3d mAb fusions and nanobodies.

Targets: C3d, complement convertases

Discontinued (2)

bempikibart — Atopic Dermatitis · primary endpoint not met in Part B; company announced intention to advance bempikibart only for AA following December 2024 topline results
ADX-097 — undisclosed · Divested via Asset Purchase Agreement with Akebia Therapeutics on November 28, 2025; Akebia is now responsible for future development and commercialization